Cross-sectional and retrospective studies on the accuracy of LUS.
| Author, year of publication | Study characteristics | LUS protocol | Results |
|---|---|---|---|
| Otaola et al., 2025 [41] | Multicenter (5 centers), cross-sectional study including RA without respiratory symptoms (n = 203) | Convex probe and linear probe14 ICS; BL numbers and PIILD by LUS: BL score ≥ 5 |
|
| Zheng et al., 2025 [39] | Monocentric, retrospective study including RA, regardless of respiratory symptoms (n = 120) | Cardiac sector probe (2.5–3.5 MHz)50 ICS; BL score = sum of BLSonographic ILD: BL > 10 |
|
| Vermant et al., 2025 [38] | Monocentric, cross-sectional study including RA, regardless of respiratory symptoms (n = 116) | Curved array probe (3.5 MHz)72 ICSNumber of BL |
|
| Schneeberger et al., 2025 [37] | Monocentric, cross-sectional study including RA, regardless of symptoms (n = 107) | Convex probe (1–8 MHz)14 ICSTotal BL score$ |
|
| Reichenberger et al., 2024 [36] | Monocentric, cross-sectional study including asymptomatic RF/ACPA-positive RA (n = 67) | Convex probe (3.5 MHz)14 ICS; PI and BL > 5Suspected ILD: LUS and PFT |
|
| Tanten Zabaleta et al., 2024 [35] | Monocentric, cross-sectional study including consecutive RA patients, regardless of symptoms and previous ILD (n = 104) | Multifrequency linear probe (8–18 MHz) and convex probe (4–8 MHz)14 ICSTotal number of BL and PI |
|
| Santos-Moreno et al., 2024 [34] | Monocentric, cross-sectional study including RA patients with clinical ILD suspicion (n = 192) | Convex probe (2–5 MHz)72 ICSBL and PI, semiquantitative and binary scores |
|
| Otaola et al., 2024 [33] | Cross-sectional study including RA patients, regardless of respiratory symptoms (n = 106) | Convex probe (1–8 MHz)14 ICSTotal number of BLLUS positive if BL ≥ 5 |
|
| Di Carlo et al., 2022 [32] | Monocentric, cross-sectional study including RA patients with suspicion of ILD (n = 72) | Linear probe (4–13 MHz)14 ICSTotal number of BL |
|
| Cogliati et al., 2014 [31] | Monocentric, cross-sectional study including RA patients with suspicion of or known ILD (n = 39) | Experienced and short-trained examiners, with convex and phased array probesStandard and pocket-sized machines, 72 ICS and 8 ICS |
|
#: Clinical-radiological score: included medical record data, radiological assessment, PFT, and HRCT into a 4-point score: 0 = normal, 1 = non-specific abnormalities, 2 = subclinical interstitial lung changes, and 3 = advanced ILD; $: total B-line score (TBLS): counting the number of BL if < 5, assigning a value of 5 if BL ≥ 5, and a value of 10 if the presence of white lung. LUS was considered positive if TBLS > 5; Ϯ: clinical score of 5 variables: male sex (3 points), crackles (3 points), age ≥ 60 years (2 points), positive RF (2 points), and ACPA positive antibodies (1 point); ACPA: anti-cyclic citrullinated peptide antibodies; AUC: area under the curve; BL: B lines; DLCO: carbon monoxide diffusion capacity; HRCT: high-resolution computed tomography; ICS: intercostal spaces; ILD: interstitial lung disease; LUS: lung ultrasound; mMRC: modified Medical Research Council; NPV: negative predictive value; NSIP: non-specific interstitial pneumonia; PFT: pulmonary function tests; PI: pleural ultrasound irregularities; RA: rheumatoid arthritis; RF: rheumatoid factor; Se: sensitivity; Sp: specificity; UIP: usual interstitial pneumonia.